Vigabatrin (Sabril) vs Vigabatrin (Vigafyde)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: GABA transaminase (GABA-T) · full Epilepsy pipeline
Vigabatrin (Sabril)
Marketed by Lundbeck LLC and partners
NCT02849457 · Phase 2 · completed
The study enrolled 84 infants, with 56 entering the randomized comparison of early vigabatrin versus matching placebo/delayed vigabatrin; participants, caregivers, and investigators were blinded. The primary clinical-function endpoint, the 24-month Bayley cognitive score, was not met: the adjusted comparison was not statistically significant (p=0.8681), so the results provide well-controlled but unclear evidence of benefit.
Reported efficacy
Cognitive Assessment Scores and Developmental Impact (24 months): Cognitive Assessment Scores and Developmental Impact (24 months): Delayed Vigabatrin (Placebo) 83.9 score on a scale ± 17.3 vs Early Vigabatrin 80.9 score on a scale ± 15.6 vs Watchful Waiting (Control Group) 97.3 score on a scale ± 16.9 vs Watchful Waiting (Open Label Vigabatrin) 85.0 score on a scale ± 21.6; p=0.8681 (Delayed Vigabatrin (Placebo) vs Early Vigabatrin) (missed)
Result source: NCT02849457
Vigabatrin (Vigafyde)
Marketed by Bora Pharmaceuticals Co., Ltd. and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Epilepsy
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Vigabatrin (Sabril) | Vigabatrin (Vigafyde) |
|---|---|---|
| Seizure frequency, % change | —Not reported | —Not reported |
| 50% responder rate | —Not reported | —Not reported |
| Seizure freedom | —Not reported | —Not reported |
Seizure frequency, % change
- Vigabatrin (Sabril)
- —Not reported
- Vigabatrin (Vigafyde)
- —Not reported
50% responder rate
- Vigabatrin (Sabril)
- —Not reported
- Vigabatrin (Vigafyde)
- —Not reported
Seizure freedom
- Vigabatrin (Sabril)
- —Not reported
- Vigabatrin (Vigafyde)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Vigabatrin (Vigafyde): no structured comparison results are available for Epilepsy.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Vigabatrin (Sabril): 3 of 4 rows · Vigabatrin (Vigafyde): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Vigabatrin (Sabril) |
|---|---|
| Dropout rate | —Early Post-randomizationa NCT02849457 · Phase 2 show 4 more results—Early Vigabatrin NCT02849457 · Phase 2 —Watchful Waiting (Open Label Vigab NCT02849457 · Phase 2 —Watchful Waiting (Open Label Vigab NCT02849457 · Phase 2 0% NCT04772547 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —Early Post-randomizationa NCT02849457 · Phase 2 show 4 more results—Early Vigabatrin NCT02849457 · Phase 2 —Watchful Waiting (Open Label Vigab NCT02849457 · Phase 2 —Watchful Waiting (Open Label Vigab NCT02849457 · Phase 2 — NCT04772547 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 51.7%Early Post-randomizationa NCT02849457 · Phase 2 show 4 more results—Early Vigabatrin NCT02849457 · Phase 2 —Watchful Waiting (Open Label Vigab NCT02849457 · Phase 2 50%Watchful Waiting (Open Label Vigab NCT02849457 · Phase 2 0% NCT04772547 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | a infections and infestations 27.6% (placebo 25.9%) respiratory, thoracic and mediastinal disorders 24.1% (placebo 14.8%) general disorders 13.8% (placebo 11.1%) NCT02849457 · Phase 2 show 1 more resultblood and lymphatic system disorders 25% (placebo 0%) general disorders 25% (placebo 11.1%) infections and infestations 25% (placebo 25.9%) NCT02849457 · Phase 2 |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Vigabatrin (Sabril)
show 1 more result
show 5 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Vigabatrin (Sabril)'s landscape · Vigabatrin (Vigafyde)'s landscape